Immunomedics, Inc. (IMMU) Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments
5/9/2013 10:19:31 AM
More...
|
Immunomedics, Inc. (IMMU) Announces Three New Patent Awards
5/7/2013 9:01:59 AM
More...
|
Immunomedics, Inc. (IMMU) Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors
4/10/2013 11:15:35 AM
More...
|
Immunomedics, Inc. (IMMU) Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer
4/9/2013 11:31:49 AM
More...
|
Immunomedics, Inc. (IMMU) Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research
4/1/2013 10:25:00 AM
More...
|
Immunomedics, Inc. (IMMU) in Collaboration With Algeta to Evaluate Potential of Epratuzumab Conjugated to Alpha-Emitter Thorium-227
1/28/2013 9:10:09 AM
More...
|
Algeta Initiates New Oncology Research Program to Evaluate the Potential of a Targeted Thorium Conjugate (TTC) Based on Immunomedics, Inc. (IMMU)'s Anti-CD22 Monoclonal Antibody
1/28/2013 8:54:02 AM
More...
|
Immunomedics, Inc. (IMMU) Announces Conference Call and Webcast for Second Quarter Fiscal 2013 Financial Results
1/25/2013 8:58:54 AM
More...
|
Immunomedics, Inc. (IMMU) Announces U.S. Patent for Hexavalent DOCK-AND-LOCK™ Complexes
1/8/2013 9:06:26 AM
More...
|
Immunomedics, Inc. (IMMU) Announces New Patent for Antibodies Targeting CD19
12/21/2012 8:50:27 AM
More...
|
|